Long‐Term Five‐Year Effectiveness of Tenofovir Alafenamide in Japanese Patients With Chronic Hepatitis B: A Prospective Multicenter Registry Study
Аннотация
ABSTRACT Background/Aims Tenofovir alafenamide (TAF) is recommended as a first‐line therapy for chronic hepatitis B (CHB); however, long‐term real‐world data in Japan are limited. This study aimed to evaluate the 5‐year efficacy of TAF in a multicenter cohort. Methods This prospective multicenter registry study included 638 patients with CHB who initiated TAF therapy between March 2019 and March 2025. The primary outcomes were the HBV‐DNA suppression rate and alanine aminotransferase (ALT) normalization rate at 5 years. Subgroup analyses were performed according to treatment history, disease stage, and renal function. Results The HBV‐DNA suppression rate increased over time and reached 97% at 5 years. Comparable suppression rates were observed between treatment‐naïve patients and patients switched from other nucleos(t)ide analogues (NAs) to TAF (97% vs. 97%, p = 1.0), as well as between patients with chronic hepatitis and those with liver cirrhosis (97% vs. 100%, p = 0.60). The overall ALT normalization rate at 5 years was 84%. Among patients switched from other NAs to TAF with detectable HBV‐DNA at baseline, 87% achieved viral suppression. In patients with renal impairment (eGFR < 60 mL/min/1.73 m 2 ), the suppression rate was 97%, comparable to those with normal renal function (97%, p = 1.0). Conclusion TAF demonstrated sustained and high antiviral efficacy over 5 years in a real‐world Japanese cohort, including in patients switched from other nucleos(t)ide analogues and those with renal impairment. These findings support the long‐term effectiveness of TAF across a broad spectrum of patients with CHB in routine clinical practice.